Abstract: The present invention provides Chlamydia proteins and methods of use in diagnostic and detection assays as well as in treatment and immunization protocols.
Type:
Grant
Filed:
May 1, 2008
Date of Patent:
May 14, 2013
Assignee:
Board of Regents, The University of Texas System
Abstract: Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6D, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit ?2) glucose 1 (1?3) glucose 2 (1?3) rhamnose (1?4) ribitol (5?phosphate. This new serotype may be included in pneumococcal vaccines.
Abstract: The present invention provides a method of inducing an immune response against Campylobacter in an avian species, especially a domesticated avian species such as chicken, turkey, duck, goose and quail, by administering, in ovo, live cells of Campylobacter.
Type:
Grant
Filed:
January 5, 2012
Date of Patent:
April 30, 2013
Assignee:
Zoetis LLC
Inventors:
Tonia Sue Agin, Everett L. Rosey, Frederick H. Weber
Abstract: An adjuvant combination that stimulates immune activation or response includes a hydrophobic immune adjuvant and a pathogen derived lipoprotein that chaperones the hydrophobic immune adjuvant to an immune receptor.
Type:
Grant
Filed:
January 26, 2010
Date of Patent:
March 26, 2013
Assignee:
Case Western Reserve University
Inventors:
Clifford V. Harding, W. Henry Boom, Michael G. Drage, Nicole D. Pecora
Abstract: A method for inducing immune tolerance to type I diabetes in a mammal by mucosal delivery of an antigen involved in the induction of type I diabetes such as pro-insulin or insulin is disclosed. The antigen involved in the induction of type I diabetes is delivered together with an IL-10 secreting micro-organism such as Lactococcus lactis and a anti-CD3 antibody.
Abstract: An L-arabinose utilizing yeast strain is provided for the production of ethanol by introducing and expressing bacterial araA, araB and araD genes. L-arabinose transporters are also introduced into the yeast to enhance the uptake of arabinose. The yeast carries additional genomic mutations enabling it to consume L-arabinose, even as the only carbon source, and to produce ethanol. A yeast strain engineered to metabolize arabinose through a novel pathway is also disclosed. Methods of producing ethanol include utilizing these modified yeast strains.
Type:
Grant
Filed:
October 21, 2010
Date of Patent:
February 12, 2013
Assignee:
Alliance for Sustainable Energy, LLC
Inventors:
Min Zhang, Arjun Singh, Pirkko Suominen, Eric Knoshaug, Mary Ann Franden, Eric Jarvis
Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.
Type:
Grant
Filed:
August 27, 2010
Date of Patent:
February 5, 2013
Assignee:
Sanaria Inc.
Inventors:
B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
Abstract: Chimeric somatostatin-based polypeptides, polynucleotides used to encode the polypeptides, the methods for isolating and producing the polypeptides and the uses thereof are provided. In addition, low cost adjuvants for enhanced immunogenic response are provided. Vaccinations that include both chimeric somatostatin-based polypeptides and novel adjuvants are included, useful in facilitating farm animal productivity.
Type:
Grant
Filed:
March 23, 2011
Date of Patent:
February 5, 2013
Assignee:
Braasch Biotech, LLC
Inventors:
Andrew R. Mendelsohn, Keith N. Haffer, James Larrick
Abstract: Disclosed herein are flagellin mutants having an enhanced activity of stimulating the toll-like receptor-5 (hereinafter referred to as “TLR5”). More specifically, disclosed are flagellin mutants, prepared by point-mutating some of the amino acids of a TRL5 agonist flagellin so as to enhance the TRL-stimulating activity of the flagellin.
Type:
Grant
Filed:
December 21, 2011
Date of Patent:
December 25, 2012
Assignee:
Industry Foundation of Chonnam National University
Inventors:
Joon Haeng Rhee, Shee Eun Lee, Soo Young Kim
Abstract: Disclosed herein are flagellin mutants having an enhanced activity of stimulating the toll-like receptor-5 (hereinafter referred to as “TLR5”). More specifically, disclosed are flagellin mutants, prepared by point-mutating some of the amino acids of a TRL5 agonist flagellin so as to enhance the TRL-stimulating activity of the flagellin.
Type:
Grant
Filed:
December 21, 2011
Date of Patent:
December 25, 2012
Assignee:
Industry Foundation of Chonnam National University
Inventors:
Joon Haeng Rhee, Shee Eun Lee, Soo Young Kim
Abstract: A vaccine is disclosed that is protective against pathogenic bacterial species, typically staphylococcal species, and includes methods to prepare said vaccine and to culture pathogenic bacteria.
Type:
Grant
Filed:
July 23, 2007
Date of Patent:
December 18, 2012
Assignee:
Vaccine Research International PLC
Inventors:
Afshan Ahmad, Bruce Robert Gordon Skinner
Abstract: The present invention relates to methods of obtaining Z. mobilis mutant strains that are more tolerant to one or more inhibitors or more capable of efficiently fermenting one or more carbohydrates. Such inhibitors include ethanol, aliphatic acids, such as acetic acid, formic acid; furan derivatives, such as 2-furaldehyde, 2-furoic acid; and phenolic compounds, such as vanillin and hydroxybenzoic acid. Such carbohydrates may include xylose, arabinose, mannose and mixtures thereof. These mutant strains may be employed to, for example, effectively and efficiently prepare ethanol from biomass.
Abstract: Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen M. tuberculosis and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.
Type:
Grant
Filed:
February 14, 2012
Date of Patent:
December 11, 2012
Assignee:
ImmportTherapeutics, Inc.
Inventors:
Philip Felgner, Xiaowu Liang, Maria Laura Gennaro
Abstract: Vaccine formulations effective against Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA) are disclosed, as well as methods of using the vaccine formulations in the treatment, prevention and prophylaxis of Staphylococcus aureus infections in a subject.
Type:
Grant
Filed:
September 23, 2009
Date of Patent:
November 27, 2012
Assignees:
University of Maryland, Baltimore, Northern Arizona University
Inventors:
Mark E. Shirtliff, Graeme O'May, Jeff Leid
Abstract: Methods and compositions are provided herein for immunizing a subject against Chlamydial genital infection by administering to the subject an effective amount of a Chlamydial immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. In some aspects, the vault-like-particles are administered to the nasal mucosa. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity at mucosal surfaces while reducing inflammation associated with Chlamydia infection.
Type:
Grant
Filed:
February 10, 2012
Date of Patent:
November 27, 2012
Assignee:
The Regents of the University of California
Inventors:
Valerie A. Kickhoefer, Leonard H. Rome, Kathleen A. Kelly, Cheryl I. Champion
Abstract: The present invention provides live, attenuated Mycoplasma gallisepticum bacteria that exhibit reduced expression of a protein identified as MGA_0621. In certain embodiments, the attenuated bacteria may additionally exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase, phosphopyruvate hydratase, 2-deoxyribose-5-phosphate aldolase, and ribosomal protein L35, relative to a wild-type M. gallisepticum bacterium. Also provided are vaccines and vaccination methods involving the use of the live, attenuated M. gallisepticum bacteria, and methods for making live attenuated M. gallisepticum bacteria. An exemplary live, attenuated strain of M. gallisepticum is provided, designated MGx+47, which was shown by proteomics analysis to exhibit significantly reduced expression of MGA_0621, and was shown to be safe and effective when administered as a vaccine against M. gallisepticum infection in chickens.
Abstract: The present invention provides enzymes capable of hydrolysing organophosphate (OP) molecules. In particular, the invention provides a phosphotriesterase enzyme identified from an Agrobacterium radiobacter strain isolated from soil that hydrolyses OP pesticides, and the gene encoding that enzyme. The invention also provides mutants of the identified phosphotriesterase enzyme which have altered substrate specificity. The use of these enzymes in bioremediation strategies is also provided.
Type:
Grant
Filed:
May 15, 2002
Date of Patent:
October 23, 2012
Assignee:
Commonwealth Scientific and Industrial Research Organisation
Abstract: The present invention provides Listeria that are attenuated for entry into non-phagocytic cells as well as a variety of methods of inducing immune responses involving administering compositions comprising the attenuated Listeria. Some of the attenuated Listeria are mutant Listeria that comprise at least one mutation in a gene encoding an invasin, such as an internalin. Some of the attenuated Listeria are further attenuated for cell-to-cell spread. Pharmaceutical compositions and vaccines useful in the methods of the invention are further provided. Methods of making and improving vaccines are also provided.
Type:
Grant
Filed:
March 29, 2010
Date of Patent:
October 16, 2012
Assignee:
Aduro Biotech, Inc.
Inventors:
Thomas W. Dubensky, Jr., Dirk G. Brockstedt, David N. Cook
Abstract: Recombinant chimeric antigens comprising unmodified and modified reactive polypeptide fragments of expressed product of the recombinant 56 kDa proteins of multiple strain of scrub typhus, such as Karp, Kato (Ktr56), Gilliam (Gmr56), and TA763 (TAr56). The invention is useful for detecting prior exposure to a number of strains of scrub typhus, based on the strength of reaction toward the chimeric protein and as a component in vaccine formulations and production of immune globulins for passive prophylaxis and immunity in subjects against heterologous infections.
Type:
Grant
Filed:
February 13, 2012
Date of Patent:
October 16, 2012
Assignee:
The United States of America as Represented by the Secretary of the Navy